Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O15120
UPID:
PLCB_HUMAN
Alternative names:
1-acylglycerol-3-phosphate O-acyltransferase 2; Lysophosphatidic acid acyltransferase beta
Alternative UPACC:
O15120; O00516; O15106; Q5VUD3; Q5VUD4; Q9BSV7; Q9BWR7
Background:
The 1-acyl-sn-glycerol-3-phosphate acyltransferase beta, also known as 1-acylglycerol-3-phosphate O-acyltransferase 2 and Lysophosphatidic acid acyltransferase beta, plays a crucial role in lipid metabolism. It catalyzes the conversion of lysophosphatidic acid (LPA) into phosphatidic acid (PA), a key intermediate in the biosynthesis of various lipids.
Therapeutic significance:
Congenital generalized lipodystrophy 1, a disorder marked by severe insulin resistance and lack of adipose tissue, is linked to mutations in this protein's gene. Understanding its function could lead to novel treatments for this and related metabolic conditions.